You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameObinutuzumab
Accession NumberDB08935
TypeBiotech
GroupsApproved
DescriptionObinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
Protein structureDb08935
Related Articles
Protein chemical formulaC6512H10060N1712O2020S44
Protein average weight146100.0 Da
SequencesNot Available
Synonyms
Afutuzumab
External Identifiers
  • GA-101
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gazyvainjection, solution, concentrate1000 mg/40mLintravenousGenentech, Inc.2013-11-01Not applicableUs
Gazyvasolution25 mgintravenousHoffmann La Roche Limited2014-11-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIO43472U9X8
CAS number949142-50-1
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
PharmacodynamicsObinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.
Mechanism of actionIn contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
Related Articles
AbsorptionObinutuzumab is administered intravenously, so its absorption is 100%.
Volume of distribution

Obinutuzumab has a volume of distribution of about 3.8 L.

Protein bindingObinutuzumab does not bind to plasma proteins.
Metabolism

Obinutuzumab is not metabolized by the liver.

Route of eliminationThe route of elimination of obinutuzumab was not indicated (FDA label).
Half lifeThe half life of obinutuzumab is 28.4 days.
Clearance

The clearance of obinutuzumab is 0.09L/day.

ToxicityThe most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solution, concentrateintravenous1000 mg/40mL
Solutionintravenous25 mg
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
water solubilityWater solubleNot Available
References
Synthesis Reference

Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96.

General ReferencesNot Available
External Links
ATC CodesL01XC15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (484 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.
AcebutololAcebutolol may increase the hypotensive activities of Obinutuzumab.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Obinutuzumab.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Obinutuzumab.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obinutuzumab.
AliskirenAliskiren may increase the hypotensive activities of Obinutuzumab.
AlprenololAlprenolol may increase the hypotensive activities of Obinutuzumab.
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Obinutuzumab.
AmbrisentanAmbrisentan may increase the hypotensive activities of Obinutuzumab.
AmlodipineAmlodipine may increase the hypotensive activities of Obinutuzumab.
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Obinutuzumab.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Obinutuzumab.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Obinutuzumab.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Obinutuzumab.
AtenololAtenolol may increase the hypotensive activities of Obinutuzumab.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Obinutuzumab.
BelimumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belimumab.
BenazeprilBenazepril may increase the hypotensive activities of Obinutuzumab.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Obinutuzumab.
BepridilBepridil may increase the hypotensive activities of Obinutuzumab.
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab.
BetaxololBetaxolol may increase the hypotensive activities of Obinutuzumab.
BethanidineBethanidine may increase the hypotensive activities of Obinutuzumab.
BevacizumabBevacizumab may increase the cardiotoxic activities of Obinutuzumab.
BimatoprostBimatoprost may increase the hypotensive activities of Obinutuzumab.
BisoprololBisoprolol may increase the hypotensive activities of Obinutuzumab.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.
BosentanBosentan may increase the hypotensive activities of Obinutuzumab.
BretyliumBretylium may increase the hypotensive activities of Obinutuzumab.
BrimonidineBrimonidine may increase the hypotensive activities of Obinutuzumab.
BupranololBupranolol may increase the hypotensive activities of Obinutuzumab.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.
CandesartanCandesartan may increase the hypotensive activities of Obinutuzumab.
CandoxatrilCandoxatril may increase the hypotensive activities of Obinutuzumab.
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Obinutuzumab.
CaptoprilCaptopril may increase the hypotensive activities of Obinutuzumab.
CarteololCarteolol may increase the hypotensive activities of Obinutuzumab.
CarvedilolCarvedilol may increase the hypotensive activities of Obinutuzumab.
CeliprololCeliprolol may increase the hypotensive activities of Obinutuzumab.
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Obinutuzumab.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Obinutuzumab.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Obinutuzumab.
CilazaprilCilazapril may increase the hypotensive activities of Obinutuzumab.
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Obinutuzumab.
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Obinutuzumab.
ClonidineClonidine may increase the hypotensive activities of Obinutuzumab.
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Obinutuzumab.
ClozapineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clozapine.
CryptenamineCryptenamine may increase the hypotensive activities of Obinutuzumab.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.
CyclothiazideCyclothiazide may increase the hypotensive activities of Obinutuzumab.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Obinutuzumab.
DebrisoquinDebrisoquin may increase the hypotensive activities of Obinutuzumab.
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Obinutuzumab.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab.
DeserpidineDeserpidine may increase the hypotensive activities of Obinutuzumab.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Obinutuzumab.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Obinutuzumab.
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Obinutuzumab.
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Obinutuzumab.
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Obinutuzumab.
DiazoxideDiazoxide may increase the hypotensive activities of Obinutuzumab.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Obinutuzumab.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Obinutuzumab.
DigoxinDigoxin may decrease the cardiotoxic activities of Obinutuzumab.
DiltiazemDiltiazem may increase the hypotensive activities of Obinutuzumab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.
DorzolamideDorzolamide may increase the hypotensive activities of Obinutuzumab.
DoxazosinDoxazosin may increase the hypotensive activities of Obinutuzumab.
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Obinutuzumab.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Obinutuzumab.
EfonidipineEfonidipine may increase the hypotensive activities of Obinutuzumab.
EnalaprilEnalapril may increase the hypotensive activities of Obinutuzumab.
EnalaprilatEnalaprilat may increase the hypotensive activities of Obinutuzumab.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab.
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Obinutuzumab.
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Obinutuzumab.
EprosartanEprosartan may increase the hypotensive activities of Obinutuzumab.
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.
FelodipineFelodipine may increase the hypotensive activities of Obinutuzumab.
FenoldopamFenoldopam may increase the hypotensive activities of Obinutuzumab.
FingolimodObinutuzumab may increase the immunosuppressive activities of Fingolimod.
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Obinutuzumab.
FosinoprilFosinopril may increase the hypotensive activities of Obinutuzumab.
GuanabenzGuanabenz may increase the hypotensive activities of Obinutuzumab.
GuanadrelGuanadrel may increase the hypotensive activities of Obinutuzumab.
GuanethidineGuanethidine may increase the hypotensive activities of Obinutuzumab.
GuanfacineGuanfacine may increase the hypotensive activities of Obinutuzumab.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Obinutuzumab.
HexamethoniumHexamethonium may increase the hypotensive activities of Obinutuzumab.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Obinutuzumab.
HydralazineHydralazine may increase the hypotensive activities of Obinutuzumab.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Obinutuzumab.
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Obinutuzumab.
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obinutuzumab.
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Obinutuzumab.
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.
IndapamideIndapamide may increase the hypotensive activities of Obinutuzumab.
IndenololIndenolol may increase the hypotensive activities of Obinutuzumab.
IndoraminIndoramin may increase the hypotensive activities of Obinutuzumab.
IrbesartanIrbesartan may increase the hypotensive activities of Obinutuzumab.
IsradipineIsradipine may increase the hypotensive activities of Obinutuzumab.
LabetalolLabetalol may increase the hypotensive activities of Obinutuzumab.
LacidipineLacidipine may increase the hypotensive activities of Obinutuzumab.
LatanoprostLatanoprost may increase the hypotensive activities of Obinutuzumab.
LeflunomideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Leflunomide.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.
LercanidipineLercanidipine may increase the hypotensive activities of Obinutuzumab.
LisinoprilLisinopril may increase the hypotensive activities of Obinutuzumab.
LofexidineLofexidine may increase the hypotensive activities of Obinutuzumab.
LosartanLosartan may increase the hypotensive activities of Obinutuzumab.
MacitentanMacitentan may increase the hypotensive activities of Obinutuzumab.
ManidipineManidipine may increase the hypotensive activities of Obinutuzumab.
MecamylamineMecamylamine may increase the hypotensive activities of Obinutuzumab.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Obinutuzumab.
MethyldopaMethyldopa may increase the hypotensive activities of Obinutuzumab.
MetipranololMetipranolol may increase the hypotensive activities of Obinutuzumab.
MetolazoneMetolazone may increase the hypotensive activities of Obinutuzumab.
MetoprololMetoprolol may increase the hypotensive activities of Obinutuzumab.
MibefradilMibefradil may increase the hypotensive activities of Obinutuzumab.
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Obinutuzumab.
MinoxidilMinoxidil may increase the hypotensive activities of Obinutuzumab.
MoexiprilMoexipril may increase the hypotensive activities of Obinutuzumab.
MoxonidineMoxonidine may increase the hypotensive activities of Obinutuzumab.
NadololNadolol may increase the hypotensive activities of Obinutuzumab.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.
NatalizumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Obinutuzumab.
NebivololNebivolol may increase the hypotensive activities of Obinutuzumab.
NicardipineNicardipine may increase the hypotensive activities of Obinutuzumab.
NicorandilNicorandil may increase the hypotensive activities of Obinutuzumab.
NiguldipineNiguldipine may increase the hypotensive activities of Obinutuzumab.
NilvadipineNilvadipine may increase the hypotensive activities of Obinutuzumab.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.
NimodipineNimodipine may increase the hypotensive activities of Obinutuzumab.
NisoldipineNisoldipine may increase the hypotensive activities of Obinutuzumab.
NitrendipineNitrendipine may increase the hypotensive activities of Obinutuzumab.
NitroprussideNitroprusside may increase the hypotensive activities of Obinutuzumab.
OlmesartanOlmesartan may increase the hypotensive activities of Obinutuzumab.
OmapatrilatOmapatrilat may increase the hypotensive activities of Obinutuzumab.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Obinutuzumab.
OuabainOuabain may decrease the cardiotoxic activities of Obinutuzumab.
OxprenololOxprenolol may increase the hypotensive activities of Obinutuzumab.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.
PargylinePargyline may increase the hypotensive activities of Obinutuzumab.
PenbutololPenbutolol may increase the hypotensive activities of Obinutuzumab.
PentoliniumPentolinium may increase the hypotensive activities of Obinutuzumab.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Obinutuzumab.
PerindoprilPerindopril may increase the hypotensive activities of Obinutuzumab.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Obinutuzumab.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Obinutuzumab.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Obinutuzumab.
PhentolaminePhentolamine may increase the hypotensive activities of Obinutuzumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.
PinacidilPinacidil may increase the hypotensive activities of Obinutuzumab.
PindololPindolol may increase the hypotensive activities of Obinutuzumab.
PolythiazidePolythiazide may increase the hypotensive activities of Obinutuzumab.
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Obinutuzumab.
PrazosinPrazosin may increase the hypotensive activities of Obinutuzumab.
PropranololPropranolol may increase the hypotensive activities of Obinutuzumab.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Obinutuzumab.
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Obinutuzumab.
QuinaprilQuinapril may increase the hypotensive activities of Obinutuzumab.
Rabies vaccineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rabies vaccine.
RamiprilRamipril may increase the hypotensive activities of Obinutuzumab.
RemikirenRemikiren may increase the hypotensive activities of Obinutuzumab.
RescinnamineRescinnamine may increase the hypotensive activities of Obinutuzumab.
ReserpineReserpine may increase the hypotensive activities of Obinutuzumab.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Obinutuzumab.
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Obinutuzumab.
RiociguatRiociguat may increase the hypotensive activities of Obinutuzumab.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.
RoflumilastRoflumilast may increase the immunosuppressive activities of Obinutuzumab.
SaprisartanSaprisartan may increase the hypotensive activities of Obinutuzumab.
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Obinutuzumab.
SelexipagSelexipag may increase the hypotensive activities of Obinutuzumab.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Obinutuzumab.
SitaxentanSitaxentan may increase the hypotensive activities of Obinutuzumab.
SpiraprilSpirapril may increase the hypotensive activities of Obinutuzumab.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Obinutuzumab.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Obinutuzumab.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab.
TelmisartanTelmisartan may increase the hypotensive activities of Obinutuzumab.
TemocaprilTemocapril may increase the hypotensive activities of Obinutuzumab.
TerlipressinTerlipressin may increase the hypotensive activities of Obinutuzumab.
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Obinutuzumab.
TiboloneTibolone may increase the hypotensive activities of Obinutuzumab.
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Obinutuzumab.
TicrynafenTicrynafen may increase the hypotensive activities of Obinutuzumab.
TimololTimolol may increase the hypotensive activities of Obinutuzumab.
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Obinutuzumab.
TofacitinibObinutuzumab may increase the immunosuppressive activities of Tofacitinib.
TolazolineTolazoline may increase the hypotensive activities of Obinutuzumab.
TorasemideTorasemide may increase the hypotensive activities of Obinutuzumab.
TrandolaprilTrandolapril may increase the hypotensive activities of Obinutuzumab.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Obinutuzumab.
TrastuzumabTrastuzumab may increase the neutropenic activities of Obinutuzumab.
TravoprostTravoprost may increase the hypotensive activities of Obinutuzumab.
TreprostinilTreprostinil may increase the hypotensive activities of Obinutuzumab.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Obinutuzumab.
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Obinutuzumab.
TrimazosinTrimazosin may increase the hypotensive activities of Obinutuzumab.
TrimethaphanTrimethaphan may increase the hypotensive activities of Obinutuzumab.
UnoprostoneUnoprostone may increase the hypotensive activities of Obinutuzumab.
ValsartanValsartan may increase the hypotensive activities of Obinutuzumab.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Obinutuzumab.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Obinutuzumab.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Obinutuzumab.
XylometazolineXylometazoline may increase the hypotensive activities of Obinutuzumab.
Food Interactions
  • Echinacea: diminished therapeutic effect of immunosuppressants

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Mhc class ii protein complex binding
Specific Function:
This protein may be involved in the regulation of B-cell activation and proliferation.
Gene Name:
MS4A1
Uniprot ID:
P11836
Molecular Weight:
33076.99 Da
References
  1. Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96. [PubMed:19513948 ]
Comments
comments powered by Disqus
Drug created on January 05, 2014 13:42 / Updated on August 17, 2016 12:24